Author:
Pacilio Massimiliano,Ventroni Guido,De Vincentis Giuseppe,Cassano Bartolomeo,Pellegrini Rosanna,Di Castro Elisabetta,Frantellizzi Viviana,Follacchio Giulia Anna,Garkavaya Tatiana,Lorenzon Leda,Ialongo Pasquale,Pani Roberto,Mango Lucio
Publisher
Springer Science and Business Media LLC
Subject
Radiology Nuclear Medicine and imaging,General Medicine,Radiology Nuclear Medicine and imaging,General Medicine
Reference42 articles.
1. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243s–9s.
2. Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, et al. MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of α-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51:311–28.
3. Hobbs RF, Song H, Watchman CJ, Bolch WE, Aksnes AK, Ramdahl T, et al. A bone marrow toxicity model for Ra-223 α-emitter radiopharmaceutical therapy. Phys Med Biol. 2012;57:3207–22.
4. CTEP. Common terminology criteria for adverse events (CTCAE) v4.0. Bethesda, MD: Cancer Therapy Evaluation Program, National Cancer Institute; 2015. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . Accessed 1 Aug 2015.
5. Nilsson S, Larsen RH, Fossa SD, Balteskard L, Borch KW, Westlin JE, et al. First clinical experience with α-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11:4451–9.
Cited by
117 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献